Joseph Cappello - 25 Jan 2023 Form 3 Insider Report for GENELUX CORP (GNLX)

Role
VP, Pharmaceutical Development
Signature
/s/ Sean Ryder, J.D., Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
25 Jan 2023
Net transactions value
$0
Form type
3
Filing time
25 Jan 2023, 18:24:30 UTC
Next filing
02 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GNLX Stock Option (right to buy) 25 Jan 2023 Common Stock 50,000 $9.00 Direct F1
holding GNLX Stock Option (right to buy) 25 Jan 2023 Common Stock 16,666 $9.00 Direct F1
holding GNLX Stock Option (right to buy) 25 Jan 2023 Common Stock 80,000 $10.50 Direct F1
holding GNLX Stock Option (right to buy) 25 Jan 2023 Common Stock 13,333 $10.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 25% of the shares shall vest on September 24, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.